KalVista Pharmaceuticals Reports Net Loss of $92.9 Million for Fiscal Year 2023
Revenue Remains Unchanged as KalVista Pharmaceuticals Releases Annual Financial Results
KalVista Pharmaceuticals, Inc.(KALV), a pharmaceutical company specializin g in the development of innovative therapies, has announced its financial results for the fiscal year ending April 30, 2023. The company reported a net loss of $92.9 million for the year, with no revenue generated during this period. Despite the loss, KalVista Pharmaceuticals remains committed to advancing its research and development efforts to bring novel treatments to patients in need.
Net Loss of $92.9 Million Reflects Ongoing Investment in Research and Development
KalVista Pharmaceuticals experienced a net loss of $92.9 million for the fiscal year 2023. This loss can be attributed to the significant investment made by the company in research and development activities. The company's dedication to advancing its pipeline of potential therapies has been a key driver behind this financial result.
Revenue Stays at Zero
